Study guide
4.2 Dosage Form Formulation & Excipients
PSI Equivalence Examination Third Country Qualification Recognition
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & TCQR Framework
1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment
2 Chapter 2: Pharmaceutical Calculations
2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions
3 Chapter 3: Pharmacology & Applied Pharmacokinetics
3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
4 Chapter 4: Basic Science & Pharmaceutics
4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence
5 Chapter 5: Pharmacy Practice & Dispensing Workflow
5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services
6 Chapter 6: Irish Pharmacy Law & Professional Ethics
6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct
7 Chapter 7: Clinical Therapeutics & Disease State Management
7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care
8 Chapter 8: OSCE & Practical Clinical Communication Skills
8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement
4.2 Dosage Form Formulation & Excipients
Key Takeaways Explain This Topic AI
Tablets require specific functional excipients: binders provide mechanical strength, disintegrants promote rapid breakup, and lubricants reduce ejection friction.
Modified-release dosage forms utilize insoluble polymeric matrix systems or pH-sensitive enteric polymers to alter in vivo dissolution kinetics.
The Hydrophilic-Lipophilic Balance (HLB) scale dictates surfactant selection: low HLB (3-6) yields water-in-oil (W/O) emulsions, while high HLB (8-16) yields oil-in-water (O/W) emulsions.
Parenteral products must comply with stringent requirements for sterility, isotonicity (approx. 290 mOsmol/kg), and bacterial endotoxin limits evaluated by the LAL assay.
Chemical and physical excipient incompatibilities, such as Maillard browning between reducing sugars and primary amines, can degrade product quality and bioavailability.
Last updated: July 2026
4.2 Dosage Form Formulation & Excipients
Core Concept: A finished pharmaceutical dosage form is a complex drug delivery system comprising active pharmaceutical ingredients (APIs) and non-therapeutic inert substances known as excipients . Formulation design transforms raw drug molecules into stable, effective, reproducible, and patient-compliant dosage forms.
1. Solid Dosage Forms: Tablets, Capsules, and Modified-Release Systems
Solid dosage forms account for over 70 % 70\% 70% of all administered pharmaceuticals due to their dosing accuracy, stability, ease of self-administration, and cost-effective manufacturing.
Tablet Manufacturing Technologies
Tablets are solid unit dosage forms prepared by compressing uniform volumes of particle formulations inside a die cavity using upper and lower punches.
Direct Compression: Blending API directly with compressible excipients (e.g., microcrystalline cellulose, spray-dried lactose) followed by compression. Ideal for moisture- and heat-sensitive APIs but requires excellent powder flowability and compressibility.
Wet Granulation: Liquid binder is added to powder mixtures to form wet granules, which are dried, milled, and compressed. Improves content uniformity and flow for low-dose or poorly flowable drugs.
Dry Granulation (Roller Compaction/Slugging): Powder blend is compacted under high mechanical pressure into ribbons or slugs, then milled into granules. Used for moisture-sensitive APIs with poor flow.
Modified-Release Oral Dosage Forms
Conventional immediate-release (IR) formulations release API rapidly upon administration. Modified-release (MR) formulations alter release location or rate:
Extended-Release (ER/CR/SR): Maintains therapeutic drug concentrations in blood over prolonged intervals (e.g., 12 − 24 hours 12-24 \text{ hours} 12 − 24 hours ). Mechanisms include:
Hydrophilic Matrix Systems: Polymeric networks (e.g., HPMC) hydrate upon contact with water, forming a viscous gel layer through which drug diffuses.
Osmotic-Controlled Release (OROS): Rigid semipermeable membrane encloses an osmotic core with a laser-drilled orifice. Water influx creates hydrostatic pressure, pumping drug out at a precise zero-order rate independent of GI p H p H p H or motility.
Delayed-Release (Enteric Coated): Protects stomach mucosa from irritating drugs or protects acid-labile drugs (e.g., omeprazole) from gastric degradation. Utilizes p H p H p H -sensitive polymers (e.g., cellulose acetate phthalate, Eudragit L/S) that remain insoluble in acidic gastric juice ( p H < 3 p H < 3 p H < 3 ) but dissolve rapidly in duodenal fluid ( p H > 5.5 p H > 5.5 p H > 5.5 ).
2. Liquid Dosage Forms, Disperse Systems, and Surfactant Physics
Liquid dosage forms comprise monophasic solutions and polyphasic disperse systems (suspensions and emulsions).
Suspensions and Stokes' Law
Suspensions are coarse dispersions of insoluble solid API particles ( > 0.5 μ m > 0.5 \ \mu\text{m} > 0.5 μ m ) suspended in a liquid medium. Physical stability requires minimizing particle sedimentation velocity ( v v v ), defined by Stokes' Law : v = d 2 ⋅ ( ρ p − ρ f ) ⋅ g 18 ⋅ η v = \frac{d^2 \cdot (\rho_p - \rho_f) \cdot g}{18 \cdot \eta} v = 18 ⋅ η d 2 ⋅ ( ρ p − ρ f ) ⋅ g
- Parameter Symbol Formulation Optimization Strategy
- Particle diameter d d d Reduce particle size via micronization to decrease v v v
- Particle density ρ p \rho_p ρ p Density matching between particle and liquid medium
- Medium density ρ f \rho_f ρ f Adjust vehicle density using syrup or polyols
- Viscosity η \eta η Increase vehicle viscosity using hydrocolloids (xanthan gum, CMC)
Formulations are structured as flocculated systems , where weak van der Waals attraction forms loose particle aggregates (flocs). Although flocs sediment rapidly, they form a porous volume that is easily resuspended upon shaking, preventing dense, irreversible caking.
Emulsions and Surfactant HLB Values
Emulsions are thermodynamically unstable systems consisting of two immiscible liquid phases stabilized by an emulsifying agent (surfactant) .
Surfactants reduce interfacial tension by orienting their hydrophilic heads and lipophilic tails across phase boundaries. Surfactants are classified using the Hydrophilic-Lipophilic Balance (HLB) scale (Griffin scale, range 1 − 20 1-20 1 − 20 ): HLB = 20 × M h M \text{HLB} = 20 \times \frac{M_h}{M} HLB = 20 × M M h
where M h M_h M h is the molecular mass of the hydrophilic portion and M M M is total molecular mass. HLB Value: 1 ----- 3 ----------- 6 ----- 8 --------------- 16 ----- 18 - 20
Function: [ antifoam ] [ W/O emulsifiers ] [ wetting ] [ O/W emulsifiers ] [ solubilizers ]
- HLB Range Primary Application Example Surfactant
- 3 − 6 3 - 6 3 − 6 Water-in-Oil (W/O) Emulsifiers Sorbitan monooleate (Span 80)
- 7 − 9 7 - 9 7 − 9 Wetting and Spreading Agents Poloxamers
- 8 − 16 8 - 16 8 − 16 Oil-in-Water (O/W) Emulsifiers Polysorbate 80 (Tween 80)
- 13 − 15 13 - 15 13 − 15 Detergents Sodium lauryl sulfate (SLS)
- 15 − 18 15 - 18 15 − 18 Solubilizers for lipophilic APIs Polyethoxylated castor oil (Cremophor EL)
- 3. Parenteral Formulations: Sterility, Isotonicity, and Pyrogen Control
Parenteral dosage forms (intravenous, intramuscular, subcutaneous) bypass the body's protective epithelial barriers, demanding absolute quality control standards.
Sterility and Endotoxin Limits
Sterility: Absolute absence of viable microorganisms, verified by Sterility Testing (USP < 71 > <71> < 71 > ).
Bacterial Endotoxins (Pyrogens): Toxic lipopolysaccharides (LPS) derived from Gram-negative bacterial outer membranes. Pyrogens cause severe febrile responses and septic shock upon injection. Endotoxin limits are quantified using the Limulus Amebocyte Lysate (LAL) assay (USP < 85 > <85> < 85 > ), which uses horseshoe crab blood lysate to form gel clots in the presence of endotoxins.
Depyrogenation: Endotoxins are heat-stable and resist autoclaving; depyrogenation requires dry heat incineration at ≥ 250 ∘ C \ge 250^\circ\text{C} ≥ 25 0 ∘ C for at least 30 minutes.
Isotonicity Calculations
Parenteral solutions must be isotonic with human blood plasma (approx. 290 mOsmol/kg 290 \text{ mOsmol/kg} 290 mOsmol/kg or Δ T f = 0.52 ∘ C \Delta T_f = 0.52^\circ\text{C} Δ T f = 0.5 2 ∘ C ) to prevent red blood cell hemolysis (hypertonic shrinkage or hypotonic lysis).
Isotonicity adjustment using the Sodium Chloride Equivalent ( E E E -value) method: E = 17 × L iso M W E = 17 \times \frac{L_{\text{iso}}}{MW} E = 17 × M W L iso
where E E E represents the grams of N a C l NaCl N a Cl equivalent to 1 g 1 \text{ g} 1 g of drug. The required N a C l NaCl N a Cl addition per 100 mL 100 \text{ mL} 100 mL is: Grams N a C l Needed = 0.90 % − ∑ ( C drug × E ) \text{Grams } NaCl \text{ Needed} = 0.90\% - \sum (C_{\text{drug}} \times E) Grams N a Cl Needed = 0.90% − ∑ ( C drug × E )
4. Excipient Functions and Incompatibilities
Excipients perform specific functional roles but can undergo detrimental chemical or physical interactions with APIs:
Excipient Class Functional Role Common Examples Incompatibility / Safety Warning
Binders Provide cohesive strength in granules Povidone (PVP), Starch, HPMC Excess binder delays tablet disintegration
Disintegrants Promote rapid tablet breakup in fluid Croscarmellose sodium, Sodium starch glycolate Moisture absorption can lead to premature degradation
Lubricants Reduce friction between die wall & tablet Magnesium stearate, Stearic acid Over-mixing creates hydrophobic coating, reducing dissolution
Preservatives Prevent microbial growth in liquids Benzalkonium chloride, Parabens Inactivated by non-ionic surfactants (e.g., polysorbates)
Diluents Bulking agent to achieve tablet size Lactose, Dicalcium phosphate, Mannitol Maillard Reaction: Lactose (reducing sugar) reacts with primary amines to form brown adducts
Critical Incompatibility Mechanisms
Maillard Reaction: Reducing sugars (such as lactose or dextrose) undergo nucleophilic addition with drugs containing primary or secondary amine groups (e.g., fluoxetine, hydrochlorothiazide), leading to brown discoloration and active potency loss.
Magnesium Stearate Hydrophobic Waterproofing: Prolonged blending of magnesium stearate coats drug particles in a hydrophobic film, dramatically slowing tablet wetting and drug dissolution rate.